Search

Strengthening Resilience and Fostering Collaboration: Ensuring a Transparent and Reliable Supply Chain for Plasma-Derived Products

The issue of immunoglobulin shortages and the importance of enhancing and maintaining plasma supplies have gained significant attention within the policy and regulatory landscape of the European Union.

Read more

Mini-hormone fights iron

Iron overload commonly leads to organ damage and even death. Currently available treatments for iron overload are burdensome or cause side effects.

Read more

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

Read more

Selected EMA news

Most of EHA’s regulatory activities focus on collaboration with the European Medicines Agency (EMA).

Read more

European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL)

The specialized working group on adult acute lymphoblastic leukemia (EWALL) consists mainly of the members of the EWALL group, which is the European Working Group for Adult ALL, and which includes the leaders of the national ALL study groups in Europe.…

Read more

EHA Lymphoma Group

The EHA Lymphoma Group (EHA LyG) is a specialized working group that was established in 2014.

Read more

Health Technology Assessment (HTA)

Every European citizen should have access to the best quality medical care at the best possible price. Pan-European cooperation on health technology assessments (HTA) is essential for such aspirations.

Read more

GAPP Joint Action

Joint Actions are projects designed and financed by Member State Authorities and the EU to address specific priorities under the EU Health Program.

Read more

EHA Education & Mentoring Award

“Educating and mentoring are a brain to pick, an ear to listen, and a push in the right direction.

Read more